Roche’s RHHBY member company, Genentech, announced the FDA approval of TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in adults. As a ...

The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades. It offers a significant advantage over alteplase by enabling ...

Recombinant human prourokinase is noninferior to alteplase in acute ischemic stroke, with symptomatic intracranial hemorrhage and major bleeding decreased.

It is the second FDA-approved treatment for acute ischemic stroke, the other being Activase (alteplase), also manufactured by Genentech, the release said. Tenecteplase is the first acute ischemic ...

Tenecteplase thus officially joins the other stroke thrombolytic approved stateside, alteplase (Activase), which is also marketed by Genentech. Notably, off-label tenecteplase had already become the ...

TNKase can be shot into the arm in five seconds, making it a faster treatment option compared to its forerunner, Activase (alteplase), which was approved for heart attack in 1987 and for stroke in ...

TNKase is delivered as a single five-second intravenous bolus. This is considerably faster than the standard of care, ...

The approval is based on a large multi-center non-inferiority study demonstrating that TNKase is comparable to Activase in AIS patients in terms of safety and efficacy. The AcT (Alteplase compared ...